Kuscher Katrin, Danelon Gabriela, Paoletti Samantha, Stefano Luisa, Schiraldi Milena, Petkovic Vibor, Locati Massimo, Gerber Basil O, Uguccioni Mariagrazia
Institute for Research in Biomedicine, Bellinzona, Switzerland.
Eur J Immunol. 2009 Apr;39(4):1118-28. doi: 10.1002/eji.200838906.
The migration of monocytes to sites of inflammation is largely determined by their response to chemokines. Although the chemokine specificities and expression patterns of chemokine receptors are well defined, it is still a matter of debate how cells integrate the messages provided by different chemokines that are concomitantly produced in physiological or pathological situations in vivo. We present evidence for one regulatory mechanism of human monocyte trafficking. Monocytes can integrate stimuli provided by inflammatory chemokines in the presence of homeostatic chemokines. In particular, migration and cell responses could occur at much lower concentrations of the CCR2 agonists, in the presence of chemokines (CCL19 and CCL21) that per se do not act on monocytes. Binding studies on CCR2(+) cells showed that CCL19 and CCL21 do not compete with the CCR2 agonist CCL2. Furthermore, the presence of CCL19 or CCL21 could influence the degradation of CCL2 and CCL7 on cells expressing the decoy receptor D6. These findings disclose a new scenario to further comprehend the complexity of chemokine-based monocyte trafficking in a vast variety of human inflammatory disorders.
单核细胞向炎症部位的迁移在很大程度上取决于它们对趋化因子的反应。尽管趋化因子的特异性以及趋化因子受体的表达模式已得到明确界定,但在体内生理或病理情况下,细胞如何整合由不同趋化因子同时产生的信号,仍是一个存在争议的问题。我们提供了关于人类单核细胞迁移的一种调节机制的证据。在稳态趋化因子存在的情况下,单核细胞能够整合由炎症趋化因子提供的刺激。特别是,在本身不作用于单核细胞的趋化因子(CCL19和CCL21)存在时,迁移和细胞反应可能在低得多的CCR2激动剂浓度下发生。对CCR2(+)细胞的结合研究表明,CCL19和CCL21不会与CCR2激动剂CCL2竞争。此外,CCL19或CCL21的存在可能会影响表达诱饵受体D6的细胞上CCL2和CCL7的降解。这些发现揭示了一种新情况,有助于进一步理解在多种人类炎症性疾病中基于趋化因子的单核细胞迁移的复杂性。